Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation

Table 1 Clinicopathological features of the study population (n = 31)

Gender (Male/female)	29/2
Age (mean/range) (yr)	49/37-62
Primary liver disease (HBV cirrhosis/HCV cirrhosis)	30/1
TNM stage (I-II/III-IVa)	12/19
Milan criteria (within/beyond)	15/16
Tumor diameter (< 5 cm/≥ 5 cm)	16/15
Tumor number (< 3/≥ 3)	26/5
Vascular invasion (present/absent)	16/15
Serum AFP ( ≤ 20 μg/L/> 20 μg/L)	11/20
Histological differentiation (good/moderate and poor)	6/25

HBV: Hepatitis B virus; HCV: Hepatitis C virus; TNM: Tumor, node and metastasis; AFP: α fetoprotein.

Table 2 Correlation between glypican-3 expression and clinicopathological features in 31 orthotopic liver transplantation patients with hepatocellular carcinoma

Variable	GPC3 protein expression(n/N) (%)	Pvalue	GPC3 mRNA overexpression (n/N) (%)	Pvalue
TNM stage
I-II	7/12 (58)		6/12 (50)
III-IVa	14/19 (74)	0.373	14/19 (74)	0.179
Milan criteria
Within	11/15 (73)		8/15 (53)
Beyond	10/16 (62)	0.519	12/16 (75)	0.208
Tumor diameter
< 5 cm	11/16 (69)		9/16 (56)
≥ 5 cm	10/15 (67)	0.901	11/15 (73)	0.320
Tumor number
< 3	18/26 (69)		17/26 (65)
≥ 3	3/5 (60)	0.686	3/5 (60)	0.818
Vascular invasion
Present	14/16 (87)		14/16 (87)
Absent	7/15 (47)	0.015	6/15 (40)	0.006
Serum AFP
≤ 20 μg/L	6/11 (54)		6/11 (54)
> 20 μg/L	15/20 (75)	0.244	14/20 (70)	0.390
Histological differentiation
Good	3/6 (50)		2/6 (33)
Moderate and poor	18/25 (72)	0.301	18/25 (72)	0.075

TNM: Tumor, node and metastasis; AFP: α fetoprotein; GPC3: Glypican-3.